The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) is a huge mover today! About 2.20M shares traded hands. Dynavax Technologies Corporation (NASDAQ:DVAX) has declined 78.44% since April 20, 2016 and is downtrending. It has underperformed by 82.99% the S&P500.
The move comes after 9 months positive chart setup for the $203.45M company. It was reported on Nov, 22 by Barchart.com. We have $5.64 PT which if reached, will make NASDAQ:DVAX worth $16.28M more.
Dynavax Technologies Corporation (NASDAQ:DVAX) Ratings Coverage
Out of 2 analysts covering Dynavax Technologies (NASDAQ:DVAX), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Dynavax Technologies has been the topic of 4 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The rating was initiated by RBC Capital Markets with “Outperform” on Monday, November 30. On Thursday, April 28 the stock rating was downgraded by RBC Capital Markets to “Sector Perform”. The rating was upgraded by Zacks on Wednesday, August 12 to “Hold”. The rating was downgraded by JP Morgan to “Neutral” on Wednesday, April 27.
According to Zacks Investment Research, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.”
Insitutional Activity: The institutional sentiment increased to 1.28 in Q2 2016. Its up 0.26, from 1.02 in 2016Q1. The ratio is positive, as 18 funds sold all Dynavax Technologies Corporation shares owned while 34 reduced positions. 10 funds bought stakes while 43 increased positions. They now own 31.67 million shares or 4.27% less from 33.08 million shares in 2016Q1.
Moreover, Lombard Odier Asset (Usa) Corporation has 0.43% invested in Dynavax Technologies Corporation (NASDAQ:DVAX) for 245,728 shares. Price T Rowe Inc Md holds 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX) for 25,780 shares. The North Carolina-based Bankshares Of America De has invested 0% in Dynavax Technologies Corporation (NASDAQ:DVAX). Blackrock Gp Ltd last reported 16,677 shares in the company. The France-based Axa has invested 0.02% in Dynavax Technologies Corporation (NASDAQ:DVAX). Earnest Prtn Llc holds 0% or 850 shares in its portfolio. Ladenburg Thalmann Services Inc accumulated 1,783 shares or 0% of the stock. Voya Ltd Liability Co owns 16,941 shares or 0% of their US portfolio. Nationwide Fund holds 0% or 24,881 shares in its portfolio. Franklin Resources has invested 0.01% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). Allianz Asset Mgmt Ag holds 117,492 shares or 0% of its portfolio. Tiaa Cref Investment Mgmt Limited Liability Company holds 0% or 136,296 shares in its portfolio. Kingdon Capital Ltd Limited Liability Company has invested 0.68% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). Bnp Paribas Arbitrage Sa has 1,631 shares for 0% of their US portfolio. Cubist Systematic Strategies owns 252 shares or 0% of their US portfolio.
More recent Dynavax Technologies Corporation (NASDAQ:DVAX) news were published by: 247Wallst.com which released: “Why Dynavax Shares Are in Freefall” on November 14, 2016. Also Globenewswire.com published the news titled: “SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Dynavax …” on November 18, 2016. Investorplace.com‘s news article titled: “Why Dynavax Technologies Corporation (DVAX), Petroleo Brasileiro SA Petrobras …” with publication date: November 14, 2016 was also an interesting one.
DVAX Company Profile
Dynavax Technologies Corporation (Dynavax), incorporated on November 6, 2000, is a clinical-stage biopharmaceutical company. The Firm uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. The Company’s development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). The Company’s lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. The Company’s SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. The Company’s advanced inflammatory disease candidate is AZD1419. The Company’s pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.